Abstract: The present invention is based, in part, on our discovery that certain types of therapeutic agents can be used in combination to treat a variety of neuropsychiatric and related disorders, including addiction (e.g., to a substance or to an activity) as well as to alleviate some of the symptoms experienced during menopause or associated with the menstrual cycle. Regardless of the precise formulation, the compositions of the invention can include at least one active ingredient that targets the hypothalamopituitary-adrenal (HPA) axis and at least one active ingredient that targets the prefrontal cortex. Either or both of these types of agents can be combined with an agent that inhibits activity in the sympathetic nervous system. Thus, the compositions or combination pharmacotherapies can also include an agent that inhibits a beta-adrenergic receptor or that otherwise acts as an anti-hypertensive or anxiolytic agent.

Abstract: A method for generating hydrogen is disclosed. The method includes substantially submersing nanowires having metallic nanoparticles into water, exposing the water submerged nanowires to light, and collecting hydrogen gas produced by photolysis from the exposure to light.

Abstract: An amorphous coating and method of fabricating the same on a substrate is disclosed. An amorphous iron based powder is located onto an aluminum alloy substrate. Pressure is applied to the powder and substrate at a processing temperature below a crystallization temperature of the powder. The powder and substrate are then spark plasma sintered for infiltrating the substrate material into the powder for resulting in a composite amorphous coating. The powder and substrate are then rapidly heated and held for 15 minutes at the processing temperature. The powder and substrate are then rapidly cooled at a cooling rate of approximately 150° C./minute. In one embodiment, the powder is comprised of Fe48Cr15Mo14Y2C15B6 alloy composition.

Abstract: A continuous segment of metallic glass material having a thickness substantially less than a width is disclosed. The continuous strip is bent into a repeating pattern of a teardrop shape providing an outer radius and an inner point defined by two adjacent radii.

Abstract: Taxanes having an ethyl ester or cyclopropyl ester substituent at C(10), a keto substituent at C(9), a hydroxy substituent at C(7), a thienyl substituent at C(3?) and a cyclobutyloxycarbamate or cyclopentyloxycarbamate substituent at C(3?), pharmaceutical compositions comprising such taxanes, methods of treatment and administration, and methods of preparation of medicaments comprising the taxanes.

Abstract: Polymers (i.e. polyesters, polyamides, and polythioesters or a mixture thereof) which degrade hydrolytically into biologically active compounds are provided. Methods of producing these polymers, intermediates useful for preparing these polymers, and methods of using these polymers to deliver biologically active compounds to a host are also provided.

Abstract: Strains of Cryptococcus flavescens which are superior antagonists of F. graminearum for suppression and control of FHB in cereals, particularly in wheat and barley, are described. The strains are prothioconazole tolerant variants of previously described C. flavescens OH 182.9 (NRRL Y-30216). Moreover, these prothioconazole tolerant variants exhibit significantly increased efficacy against F. graminearum in comparison to the parent strain OH 182.9.

Abstract: The invention relates to a polypeptide of a protective antigenic determinant (PAD polypeptide) of porcine reproductive and respiratory syndrome virus (PRRSV) and nucleic acids encoding a PAD polypeptide. The PAD polypeptide and nucleic acids encoding a PAD polypeptide are useful in the development of antibodies directed to PAD, vaccines effective in providing protection against PRRSV infection, and diagnostic assays detecting the presence of PAD antibodies generated by a PAD-specific vaccine. The invention also discloses methods of generating antibodies to PAD, for vaccinating a pig to provide protection from PRRSV infections, a method of preparing the vaccine, a method of treating PRRSV infections in a pig, and a method of detecting antibodies to PAD of PRRSV.

Abstract: A method to detect a messenger ribonucleic acid (mRNA) sequence is provided including annealing a first probe and a second probe to at least a portion of the mRNA, wherein the first and second probes do not comprise the same nucleotide sequence, wherein each probe sequence is complimentary to at least a portion of the mRNA and the second probe is a T-shaped probe having 1) a probe sequence complementary to at least a portion of the mRNA sequence and 2) a rolling circle amplification primer that is linked to an internal reactive group of the probe sequence of the second probe so as to provide physical separation of probe ligation and rolling circle amplification, said probe-connected rolling circle primer comprising a circle recognition sequence.

Abstract: A process of forming a double strand cleavage in DNA includes providing a reaction mixture containing double stranded DNA having a break in a first strand defining a target site in a second strand. The method continues by adding to the reaction mixture a photoreactive lysine conjugate selected from a lysine-enediyne conjugate, a lysine-acetylene conjugate or a combination thereof, for a time sufficient for the lysine conjugate to bind to the DNA adjacent the target site. The reaction mixture is then irradiated with electromagnetic radiation sufficient to photoactivate the lysine conjugate to cleave the second strand adjacent the target site.

Abstract: The invention provides liquid crystalline blends, a device such as a photovoltaic cell using the blend and method thereof. A liquid crystalline blend comprises at least an electron donor and at least an electron acceptor with a weight or molar ratio in the range of from about 1:20 to about 20:1. Another liquid crystalline blend comprises at least an electron donor and at least an electron acceptor, wherein the electron donor, the electron acceptor, or both is (are) halo-substituted such as F-substituted. The donor or the electron acceptor can be excited by an electromagnetic radiation such as solar light to induce electron transfer between the donor and the acceptor. The photovoltaic cell is improved in that favorable molecular arrangement in the blend gives more interfaces between the donor and the acceptor and thus a viable path for dissociation and electrons and/or holes; as well as larger light-harvesting area toward the coming light.

Abstract: The present invention provides novel photobioreactors, modules thereof, and methods for use in culturing and harvesting algae and cyanobacteria.

Abstract: Compositions for stimulating the immune system and for treating malignancies associated with overexpression of the HER-2 protein are provided. Such compositions include immunogenic epitopes of the HER-2 proteins and chimeric and multivalent peptides which comprise such epitopes. The present invention also relates to polynucleotides which encode the chimeric peptides. Also provided are pharmaceutical compositions comprising such immunogenic compositions. Methods for stimulating an immune response to HER-2 protein are provided. Methods for treating breast cancer, ovarian cancer, prostate cancer, colon cancer and lung cancer are provided.

Abstract: In accordance with exemplary embodiments, apparatus and method for biologic sample rapid collection and recovery device, and convenient storage are provided. An exemplary embodiment includes an apparatus comprising a lateral flow technology device including at least a membrane configured to bind an analyte from a sample that flows through the lateral flow technology device, in which a selected portion of the membrane bound to the analyte when placed directly in an analysis system does not substantially inhibit analysis of the analyte. An elution protocol is not required to extract the analyte bound from the selected portion before placed directly in the analysis system.

Abstract: Provided are compositions and methods for therapy of macular degeneration including dry age-related macular degeneration (dAMD), juvenile macular degenerations (JMDs) where toxic retinoids are known to accumulate as part of the pathogenesis, such as Stargardt disease, and Best disease, and neovascular wet age-related macular degeneration. The method entails administering to an individual in need of therapy for macular degeneration a first polynucleotide that can facilitate a reduction in the amount of rod opsin (RHO) mRNA in the individual; or a second polynucleotide that can facilitate a reduction in the amount of RPE65 mRNA in the individual; or a combination thereof. The polynucleotides of the invention are hammerhead ribozymes or shRNAs. The polynucleotides target a sequence in RHO mRNA or RPE65 mRNA and facilitate reduction in the target mRNA via ribozymatic cleavage of the target, or by hybridization to the target, which leads to RNAi mediated degradation of the target mRNA.

Abstract: A p-channel tunneling field effect transistor (TFET) is selected from a group consisting of (i) a multi-layer structure of group IV layers and (u) a multi-layer structure of group III-V layers. The p-channel TFET includes a channel region comprising one of a silicon-germanium alloy with non-zero germanium content and a ternary III-V alloy. An n-channel TFET is selected from a group consisting of (i) a multi-layer structure of group IV layers and (u) a multi-layer structure of group III-V layers. The n-channel TFET includes an n-type region, a p-type region with a p-type delta doping, and a channel region disposed between and spacing apart the n-type region and the p-type region. The p-channel TFET and the n-channel TFET may be electrically connected to define a complementary field-effect transistor element. TFETs may be fabricated from a silicon-germanium TFET layer structure grown by low temperature (500 degrees Centigrade) molecular beam epitaxy.

Abstract: The invention relates to Group 1 metal/silica gel compositions comprising silica gel and an alkali metal or alloy, wherein Group 1 metals or alloys are absorbed into the silica gel pores. The invention relates to producing hydrogen gas comprising contacting a Group 1 metal/silica gel composition with water, and further relates to an alkali metal reduction of an organic compound, the improvement comprising contacting the organic compound with a Group 1 metal/silica gel composition. In these embodiments, the Group 1 metal/silica gel composition reacts with dry O2. The invention also relates to producing hydrogen gas comprising contacting a Group 1 metal/silica gel composition with water, and further relates to an alkali metal reduction of an organic compound, the improvement comprising contacting the organic compound with a Group 1 metal/silica gel composition. In these embodiments, the Group 1 metal/silica gel composition produced does not react with dry O2.

Abstract: Vaccines preparations against canine parvovirus are provided. The vaccines include a novel canine parvovirus-2 isolated from a raccoon, and related nucleic acids and proteins.

Abstract: Administration of an HNO/NO? donating compound, such as Angeli's salt, increases myocardial contractility while concomitantly lowering left ventricular preload in subjects experiencing heart failure. Moreover, administration of the HNO/NO? donating compound isopropylamine (IPA)/NO (Na(CH3)2CHNHN(O)NO) surprisingly exhibited positive inotropic effects in subjects experiencing heart failure that were superior to those caused by the HNO/NO? donating compound Angeli's salt. Additionally, in contrast to the effects observed with NO donors, administration of an HNO/NO? donor in combination with a positive inotropic agent did not impair the positive inotropic effect of the positive inotropic agent. Further, HNO/NO? exerts its positive inotropic effect independent of the adrenergic system, increasing contractility even in subjects receiving beta-antagonist therapy.

Abstract: Methods for screening for modulators of autophagy are disclosed. Methods for identifying genes whose expression inhibits autophagy, as well as genes whose expression promotes autophagy, are disclosed. Also disclosed are methods for identifying compounds that stimulate autophagy, as well as compounds that inhibit autophagy. Cell lines that may be used in the methods of identification are also disclosed.